Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + Gemcitabine + Cisplatin in Metastatic Urothelial Cancer
NCT03093922Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2017
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab in urothelial carcinoma (UC) (3 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Overall Response Rate at 1 year. Started Mar 2017; status: completed.
02
Drugs
atezolizumab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03093922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03093922.